Gaudium IVF IPO Subscribed 7.27 Times on Day 3

Gaudium IVF and Women Health Limited's initial public offering (IPO) closed its three-day subscription window on a strong note, reaching 7.27 times overall subscription by 5:14 PM on Day 3 (February 24, 2026). The ₹165 crore book-build issue, priced at ₹75–₹79 per share, received bids for 10,63,50,489 shares against 1,46,20,340 shares on offer, with total applications reaching 2,49,109.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Subscription Status of Gaudium IVF IPO:

Here are the subscription details for Gaudium IVF IPO as of Day 2 (February 24, 2026):

Key Highlights – Day 3

• Overall subscription reached a strong 7.27 times on Day 3 (February 24, 2026), showing substantial improvement from Day 2's 3.03 times.
• Non-institutional investors led subscription with exceptional interest at 14.05 times, surging from Day 2's 4.64 times, with sNII recording even stronger demand at 16.73 times and bNII at 12.71 times.
• Retail investors showed strong confidence at 7.60 times, building substantially from Day 2's 4.06 times, indicating robust retail demand for this IVF healthcare IPO.
• Qualified institutional buyers (ex-anchor) recorded 1.62 times, a significant jump from Day 2's 0.02 times, indicating improved institutional appetite on the final day.
• Total applications reached 2,49,109 on Day 3.
• Anchor investors fully subscribed their allocation of ₹49.50 crores on February 19, 2026.

Key Highlights – Day 2

• Overall subscription reached 3.03 times on Day 2 (February 23, 2026), showing strong improvement from Day 1's 0.90 times.
• Non-institutional investors led Day 2 with 4.64 times, surging from Day 1's 0.91 times, with sNII at 6.87 times and bNII at 3.52 times.
• Retail investors showed healthy participation at 4.06 times, building substantially from Day 1's 1.42 times.
• Qualified institutional buyers (ex-anchor) recorded negligible participation at 0.02 times on Day 2.

Key Highlights – Day 1

• Overall subscription reached 0.90 times on Day 1 (February 20, 2026), reflecting cautious initial investor interest in this IVF healthcare IPO.
• Retail investors led opening day participation at 1.42 times, indicating solid retail appetite from the outset.
• Non-institutional investors recorded 0.91 times on Day 1, with sNII showing stronger interest at 1.65 times against bNII's 0.54 times.
• Qualified institutional buyers (ex-anchor) showed negligible participation at 0.00 times on Day 1.

About Gaudium IVF and Women Health Limited

Incorporated in March 2015, Gaudium IVF and Women Health Limited is engaged in In Vitro Fertilisation (IVF) treatments across India, operating through a hub-and-spoke model spanning over 30 locations, including seven hubs and 28 spokes. The company operates centres in Delhi (Janakpuri, Kailash Colony), Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, and serves patients from countries including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. Its specialised fertility services include IVF, Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction, alongside gynaecological care for PCOD/PCOS, endometriosis, high-risk pregnancy management, and advanced male infertility treatments.